Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Broadly Neutralizing Synthetic Cannabinoid Vaccines
Mingliang Lin, Jinny Claire Lee, Steven Blake, et al.
JACS Au (2020) Vol. 1, Iss. 1, pp. 31-40
Open Access | Times Cited: 12

Showing 12 citing articles:

Development of fentanyl-specific monoclonal antibody (mAb) to antagonize the pharmacological effects of fentanyl
Xiaoyi Chen, Li Wang, Xiao Ma, et al.
Toxicology and Applied Pharmacology (2024) Vol. 486, pp. 116918-116918
Closed Access | Times Cited: 4
Current status of vaccines for substance use disorders: A brief review of human studies
Thanh Thuy Truong, Thomas R. Kosten
Journal of the Neurological Sciences (2021) Vol. 434, pp. 120098-120098
Closed Access | Times Cited: 27
A Vaccine against Benzimidazole-Derived New Psychoactive Substances That Are More Potent Than Fentanyl
Jinny Claire Lee, Hyeri Park, Lisa M. Eubanks, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 3, pp. 2522-2531
Closed Access | Times Cited: 10
Establishment of Broad-Specificity Monoclonal Antibody-Based Immunoassay for Rapid Detection of Indole-Type and Indazole-Type Synthetic Cannabinoids and Metabolites
Xiaoyi Chen, Xiao Ma, Xin Wang, et al.
Analytical Chemistry (2024) Vol. 96, Iss. 46, pp. 18445-18454
Closed Access | Times Cited: 1
A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects
Muhammet Celik, Brian Fuehrlein
ImmunoTargets and Therapy (2022) Vol. Volume 11, pp. 55-66
Open Access | Times Cited: 7
Au-doped MOFs catalyzed electrochemiluminescence platform coupled with target-induced self-enrichment for detection of synthetic cannabinoid RCS-4
Qianying Cao, Ding Jiang, Fangmin Xu, et al.
Microchimica Acta (2022) Vol. 189, Iss. 9
Closed Access | Times Cited: 7
Family of Structurally Related Bioconjugates Yields Antibodies with Differential Selectivity against Ketamine and 6-Hydroxynorketamine
Zhen Zheng, Jillian L. Kyzer, Adam Worob, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 21, pp. 4113-4122
Open Access | Times Cited: 6
Pharmacokinetic Approach to Combat the Synthetic Cannabinoid PB-22
Mingliang Lin, Beverly A. Ellis, Lisa M. Eubanks, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 14, pp. 2573-2579
Closed Access | Times Cited: 5
Development of effective therapeutics for polysubstance use disorders
Jinny Claire Lee, Kim D. Janda
Current Opinion in Chemical Biology (2021) Vol. 66, pp. 102105-102105
Closed Access | Times Cited: 5
Synthesis, structural characterization, analytical profiling, and application to authentic samples of synthesized Phase I metabolites of the synthetic cannabinoid 5F‐MDMB‐PICA
Ruijia Chen, Zi‐hua Zhang, Shenglan Yang, et al.
Drug Testing and Analysis (2024) Vol. 16, Iss. 12, pp. 1578-1592
Closed Access
Evaluation of a hapten conjugate vaccine against the “zombie drug” xylazine
Mingliang Lin, Lisa M. Eubanks, Bin Zhou, et al.
Chemical Communications (2024) Vol. 60, Iss. 35, pp. 4711-4714
Closed Access
Development of Cross-Reactive Antibodies for the Identification and Treatment of Synthetic Cannabinoid Receptor Agonist Toxicity
Adam Worob, Cody J. Wenthur
Vaccines (2022) Vol. 10, Iss. 8, pp. 1253-1253
Open Access | Times Cited: 2
Page 1

Scroll to top